



September 25, 2007 03:43 PM US Eastern Standard Time

## **Capricor Announces Appointment of Dr. Alessandro Giacomello to Scientific Advisory Board**

Los Angeles, California – September 25, 2007. Capricor Inc. ([www.capricor.com](http://www.capricor.com)), announced today the appointment of Alessandro Giacomello M.D., Ph.D. to its Scientific Advisory Board. Dr. Giacomello laboratories at the University of Rome discovered and patented cardiac stem cells which could be derived in a unique method termed cardiospheres. The proprietary method is being commercialized under exclusive license by Capricor.

Dr. Giacomello is Full Professor of General Pathology, Sapienza University, Rome, Italy. He has focused his research activity on purine metabolism in man. Since 2002 his work has explored cardiac stem cells isolated and expanded from human heart biopsies. Dr. Giacomello graduated from University of Rome “La Sapienza” in 1973 in Medicine and Surgery and with a specialty degree in Rheumatology in 1977. He has been Faculty at the University of Rome “La Sapienza” since 1980 and Full Professor since 1986. Dr. Giacomello has served in numerous societies and institutes including President of the Scientific Committee of the European Society for the Study of Purine and Pyrimidine Metabolism, and as member of the Scientific Council at the Istituto Pasteur-Fondazione Cenci Bolognetti.

Dr. Giacomello joins scientific founder Dr. Eduardo Marbán, Head of Cedar-Sinai Heart Institute, and Dr. Roberto Bolli, Chief of the Division of Cardiology at the University of Louisville, in advising Capricor on the scientific development of its Autologous Cardiosphere Derived Cell Treatment.

Capricor Inc., currently located in Los Angeles, California, is a leading biotechnology company that specializes in discovering, developing, and commercializing biotherapeutics for the treatment of heart diseases. Capricor’s mission is to revolutionize the treatment of cardiac disease by translating novel stem cell science into therapeutics that halt and reverse the disease process for patient’s, their families, and society in general.

***Translating today's cardiac research innovations  
into tomorrow's heart therapies***